Orum Therapeutics Inc is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is principally engaged in the research and development of new biopharmaceuticals for cancer and immune diseases based on its platforms.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
23/07/26	₩47,700.00	+12.37%	102,461
22/07/26	₩42,450.00	+1.31%	71,340
21/07/26	₩41,900.00	-0.24%	96,300
20/07/26	₩42,000.00	-7.49%	72,015
16/07/26	₩45,400.00	-6.20%	61,250

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 23/07/2026			5-day change	1st Jan Change
47,700.00 ^KRW	+12.37%		-1.45%	-60.25%

07-15	Alert wrongly tagged to Orum Therapeutics withdrawn	RE
04-17	Orum Therapeutics Presents New Preclinical Data on ORM-1153, A CD123-Targeting Degrader-Antibody Conjugate	CI

Market Cap	1,036B 702M 619M 574M 528M 989M 67.86B 1.01B 6.86B 2.68B 33.22B 2.64B 2.58B 115B	P/E 2024 *	-	P/E 2025	-59.5x
Enterprise Value	929B 630M 555M 515M 474M 887M 60.85B 904M 6.15B 2.4B 29.78B 2.37B 2.31B 103B	EV / Sales 2024 *	-	EV / Sales 2025	103,580x
Free-Float	84.16%	Yield 2024 *	-	Yield 2025	-

07-15	Alert wrongly tagged to Orum Therapeutics withdrawn	RE
04-17	Orum Therapeutics Presents New Preclinical Data on ORM-1153, A CD123-Targeting Degrader-Antibody Conjugate	CI
04-13	Orum Therapeutics, Inc. Appoints Maria Koehler and Geoff Meyerson to Board of Directors	CI
01-15	Orum Therapeutics, Inc. announced that it has received KRW 24.999873175 billion in funding from a group of investors	CI
01-04	Orum Therapeutics Appoints Chad May as Chief Scientific Officer	CI
12-18	Orum Therapeutics, Inc. announced that it expects to receive KRW 24.999873175 billion in funding from a group of investors	CI
11-03	Orum Therapeutics Announces Presentation of Preclinical Data for Orm-1153 At the 2025 American Society of Hematology Annual Meeting	CI
15/10/25	Orum Therapeutics Appoints Dorin Toader as Head of Platform Technology	CI
23/06/25	Orum Therapeutics, Inc.(KOSDAQ:A475830) added to S&P Global BMI Index	CI
07/02/25	Orum Therapeutics, Inc. has completed an IPO in the amount of KRW 50 billion.	CI
16/07/24	Orum Therapeutics Announces a Global, Multi-Target License and Option Agreement with Vertex Pharmaceuticals for the Use of Orum's TPD2 Technology to Develop Novel Degrader-Antibody Conjugates	CI

12-19	Orum Therapeutics Secures Approximately US$100 Million to Accelerate Development of Leading Degrader Antibody Conjugate Programs to Treat Serious Diseases	AQ
15/10/25	Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orums Degrader-Antibody Conjugate Payload Platforms and Expand TPD Therapeutic Applications	AQ

Orum Therapeutics, Inc. Share Price

Stocks

A475830

KR7475830006

Biotechnology & Medical Research

Valuation: Orum Therapeutics, Inc.

Chart: Orum Therapeutics, Inc.

Latest news : Orum Therapeutics, Inc.

Press Releases: Orum Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Orum Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+12.37%
1 week	-1.45%
Current month	-19.43%
1 month	-20.90%
3 months	-41.33%
6 months	-54.53%
Current year	-60.25%

1 week	39,250	48,100
1 month	39,250	63,400
Current year	39,250	146,600
1 year	20,500	146,600
3 years	15,950	146,600
5 years	15,950	146,600
10 years	15,950	146,600

Manager	Title	Age	Since
Seung-Ju Lee CEO	Chief Executive Officer	52	16/08/2016
In-Tae Jeong DFI	Director of Finance/CFO	44	22/10/2023
Chad May CTO	Chief Tech/Sci/R&D Officer	-	04/01/2026

Director	Title	Age	Since
Seung-Ju Lee BRD	Director/Board Member	52	16/08/2016
In-Tae Jeong BRD	Director/Board Member	44	22/10/2023
Un-Nam Park BRD	Director/Board Member	55	31/03/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
21/02/25	Seung-Ju Lee	Free	Founder	3,388,000	-
21/02/25	Un-Nam Park	Free	Director	60,000	-
21/02/25	In-Tae Jeong	Free	Chief Financial Officer	10,000	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ORUM THERAPEUTICS, INC.	+12.37%	-1.45%	+108.30%	-	624M
WUXI APPTEC CO., LTD.	+1.23%	-3.08%	+53.96%	+87.98%	55.27B
ARGENX SE	+5.09%	+6.18%	+63.69%	+62.06%	54.15B
INSMED INCORPORATED	+0.72%	-2.19%	+4.36%	+409.54%	23.11B
BIONTECH SE	+0.25%	+0.08%	-17.39%	-15.22%	23.22B
WUXI BIOLOGICS (CAYMAN) INC.	+1.03%	-0.76%	+40.14%	-3.59%	20.33B
GENMAB A/S	-0.37%	+0.42%	+37.47%	-31.61%	17.91B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.87%	-2.80%	+37.96%	+600.00%	15.76B
PHARMAESSENTIA CORPORATION	-2.54%	-12.88%	+168.62%	+289.45%	15B
EXELIXIS, INC.	+1.22%	+0.18%	+25.14%	+182.63%	13.82B
Average	+1.99%	+0.17%	+52.23%	+175.69%	23.92B
Weighted average by Cap.	+1.59%	+1.20%	+46.65%	+138.40%

	2024	2025
Net sales	20.91B 14.17M 12.48M 11.58M 10.66M 19.96M 1.37B 20.34M 138M 53.98M 670M 53.23M 52.1M 2.33B	23.56M 15.98K 14.07K 13.05K 12.02K 22.5K 1.54M 22.93K 156K 60.84K 755K 59.99K 58.72K 2.62M
Net income	-5.74B -3.89M -3.43M -3.18M -2.93M -5.48M -376M -5.59M -38.01M -14.82M -184M -14.61M -14.3M -639M	-41.97B -28.46M -25.06M -23.25M -21.4M -40.08M -2.75B -40.84M -278M -108M -1.35B -107M -105M -4.68B
Net Debt	-90.47B -61.34M -54.01M -50.12M -46.14M -86.4M -5.93B -88.03M -599M -234M -2.9B -230M -225M -10.08B	-107B -72.62M -63.94M -59.34M -54.62M -102M -7.02B -104M -709M -277M -3.43B -273M -267M -11.93B